Cerebral Venous Thrombosis — F1 Promotion Case 3

Recognize cerebral venous thrombosis as the leading diagnosis in a young patient with unexplained bilateral deep cerebral infarctions and a thrombotic risk factor such as oral contraceptive use.

State therapeutic anticoagulation as the mainstay for confirmed CVT, including when intracranial venous infarction or hemorrhage is present unless a specific contraindication exists.

Escalate to endovascular therapy only in selected severe deterioration despite optimal medical therapy.

Acute treatment is therapeutic LMWH or UFH, selected for renal function, bleeding risk and planned procedures; UFH may be preferable when rapid reversal is likely. Venous hemorrhagic infarction by itself does not preclude anticoagulation. Stop estrogen exposure and plan specialist-directed oral anticoagulation and duration after stabilization.

Obtain appropriate venous imaging, preferably CT venography or MR venography, to confirm the diagnosis and define the extent of thrombosis.

Assess provoking factors, CBC/platelets, renal function, pregnancy/postpartum status, medications and relevant thrombophilia history when clinically appropriate.

Consider deep venous/straight-sinus thrombosis with bilateral thalamic lesions; artery-of-Percheron infarction and metabolic/infectious mimics remain alternatives. Request CT venography or MRI/MRV rather than concluding from noncontrast CT alone.

Describe the bilateral deep cerebral abnormalities shown on the source CT and recognize them as venous-territory infarction rather than assuming a typical arterial territorial stroke.

Correlate the imaging with the clinical presentation and confirm venous occlusion with dedicated venous imaging.

Consider cerebral edema, venous infarction/hemorrhage, raised intracranial pressure, seizures, propagation of thrombosis and new venous drainage impairment.

Identify the patient's worsening neurologic state as a reason for urgent reassessment and escalation.

Treat the seizure promptly, support oxygenation and protect the airway if consciousness/airway reflexes deteriorate; obtain urgent brain/venous imaging and neurocritical/neurosurgical review.

Use head elevation, avoid hypotension and manage impending herniation. Decompressive surgery is an urgent lifesaving option for mass effect/herniation and should not be delayed for a trial of endovascular rescue. Endovascular treatment is reserved for selected deterioration despite appropriate treatment.

American Heart Association 2024 — Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association. Updates the 2011 AHA statement. Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes and is diagnosed mainly by MR/CT venography; death or dependence occurs in 10% to 15% of patients despite intensive medical treatment. The statement reviews the evidence for anticoagulation and for endovascular therapy, considers craniectomy, and gives an algorithm for patients who deteriorate neurologically or show thrombus propagation despite maximal medical therapy. It is a scientific statement rather than a graded guideline, so it does not assign recommendation classes.

Strength of recommendation: expert-opinion; certainty of evidence: low.

RE-SPECT CVT (2019) — question: Is dabigatran as effective and safe as dose-adjusted warfarin for preventing recurrent venous thrombosis after cerebral venous thrombosis?

Finding: No recurrent venous thromboembolic events were seen in either group. One major bleed (intestinal) occurred on dabigatran and two (intracranial) on warfarin, with one further clinically relevant non-major bleed on warfarin. Recanalization occurred in 60.0% on dabigatran and 67.3% on warfarin.

How to apply it: RE-SPECT CVT found both anticoagulants carried a low risk of recurrence and bleeding, supporting dabigatran as a reasonable alternative to warfarin after initial heparin in stable patients. Because it was small and exploratory, it cannot show equivalence on efficacy.

Current guideline position: The 2024 AHA scientific statement on cerebral venous thrombosis discusses the evidence for anticoagulation. Initial heparin followed by an oral anticoagulant remains the standard approach.

TO-ACT (2020) — question: Does adding endovascular treatment to standard medical care improve functional outcome in severe cerebral venous thrombosis?

Finding: At 12 months, 22 of 33 patients (67%) in the endovascular group and 23 of 34 (68%) in the standard-care group had an mRS of 0 to 1. Mortality was 12% vs 3% and symptomatic intracerebral hemorrhage 3% vs 9%, neither statistically significant.

How to apply it: TO-ACT does not support routine endovascular treatment in severe CVT; anticoagulation-based care remains the foundation. Because the trial was small and stopped for futility, a benefit in a highly selected group cannot be excluded.

Current guideline position: The 2024 AHA scientific statement discusses the evidence for endovascular therapy and provides an algorithm for patients who deteriorate or have thrombus propagation despite maximal medical therapy.